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Background and objective: There have been no clinical reports on pulmonary lymphangioleio-
myomatosis (PLAM) based on large studies or epidemiological surveys in mainland China. The
purpose of this study was to provide a retrospective analysis of PLAM patients in mainland
China by reviewing the clinical data of PLAM cases reported.
Methods: The China Academic Journals Full-text Database search engine was used to collect
related cases in mainland China through the end of 2008. 120 cases met the study’s inclusion
criteria and were reviewed for this analysis.
Results: The average age of the 120 patients upon confirmed diagnosis was 37.3 6.4 years.
The average duration from onset of symptoms to a confirmed diagnosis was 29.6  35.8
months, with 80 person-time patients having experienced misdiagnosis before the confirmed
diagnosis. The major clinical manifestations of PLAM included progressive dyspnea, recurrent
pneumatothorax, refractory chylothorax. Pulmonary function abnormalities included obstruc-
tive pulmonary ventilation disorders and degenerated diffusing capacity. Ten patients were
found to be complicated with renal angiomyolipoma and 17 with abdominal or pelvic lymphan-
gioleiomyoma. Half of the patients had undergone antiestrogen therapies such as proges-
terone, and four patients received pulmonary transplantation. The average duration from
the confirmed diagnosis to death was 36.4 48.9 months among the 28 cases of death.
Conclusions: Doctors in mainland China are becoming increasingly vigilant to PLAM, although
misdiagnosis or missed diagnosis still exists. Provider attention to the correlation between
PLAM and tuberous sclerosis complex, as well as to the possible involvement of multiple
organs, is insufficient.
ª 2010 Elsevier Ltd. All rights reserved.13701640522; fax: þ86 21 54961729.
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Pulmonary lymphangioleiomyomatosis (PLAM) is an orphan
pulmonary disease that predominantly plagues fertile
women.1e3 It is characterized by a proliferation of abnormal
smoothmuscle cells (LAM cells) and cystic lesions in the lung,
manifesting in progressive dyspnea, recurrent spontaneous
pneumothorax, refractory chylothorax. The chest CT,
particularly HRCT, is capable of showing characteristic
lesions of PLAM: thin-wall cystic air sacs evenly distributed in
bilateral lobes surrounded by normal pulmonary tissues.
The incidence of PLAM is 2.6 per 1 million women without
evidence of genetic disease. However, this disease occurs in
one third of women with tuberous sclerosis complex (TSC).1
PLAM is associated with TSC gene mutations.4,5 Mutations
of TSC1 or TSC2 genes can cause defects or a deficiency in the
proteins that they encode, which undermines the modula-
tion of the transmission of downstream signals, resulting in
abnormal cell proliferation and migration.2,3
This disease was first reported by Burrell in 1937,6 fol-
lowed by continuous case reports across the world. The first
PLAM case in mainland China was confirmed in 1983.7 The
lack of an agency as authoritative as the the American
National Heart, Lung, and Blood Institute (NHLBI) in main-
land China results in an absence of case summaries based
on studies with large sample sizes, let alone an epidemio-
logical survey of PLAM cases in mainland China to date. The
purpose of this study was to provide a retrospective analysis
of PLAM patients in mainland China.Methods
Subjects
Using the China Academic Journals Full-text Database
(CAJ)dthe largest searchable full-text and full-image
interdisciplinary Chinese journal database in the world
(www.cnki.net), the subjects were identified from papers
on PLAM published in academic journals in mainland China
by the end of December of 2008. The inclusion criteria
were: 1. The patients should meet at least one provision of
the PLAM diagnostic criteria: (1) Confirmed by pulmonary
pathological biopsy, (2) Confirmed by pathological biopsy of
lymph nodes or other masses, (3) Characteristic changes on
chest HRCT, such that a clinical diagnosis is appropriate; 2.
Patients must have been living in mainland China (were not
from Taiwan, Hong Kong, Macau or other foreign nations);
and 3. The papers must provide enough detail about the
patients’ clinical data, including disease history, imaging
data, pathological results and therapeutic strategy.
After a complete search of the CAJ database and
screening for inclusion criteria, 120 cases were included in
the study which were reported by 81 papers (online
supporting information).
Methods
The CAJ was used to pool PLAM cases in mainland China
published by academic journals, after which the eligibility
of the cases were reviewed by referring to the study’sinclusion criteria. The clinical data of these cases were
then analyzed to come to understanding about the current
status of PLAM in mainland China.
Statistic methods
SPSS13.0 software was used to conduct statistic analyses.
Continuous variables were compared using independent-
sample t-test. Chi-square test was used to compare cate-
gorical variables. Differences with a value of P< 0.05 were
considered statistically significant. Because allmeasurement
values were not available for all subjects, the sample sizes
differ somewhat for different results. All data are repre-
sented in the form of means and standard deviations ðx  sÞ.
Results
Demographic data
The average age of the eligible PLAM cases upon confirmed
diagnosis was 37.3 6.4 years (range: 13e60 years). The
precise time of PLAM diagnosis confirmation was available
in the disease history data of 85 patients, one received
a confirmed diagnosis before 1990, 19 during 1990e1999
and 65 in 2000 or later. In addition, 109 of the total patients
were diagnosed by hospitals in the developed eastern
areas, 6 diagnosed by hospitals in the less developed
central areas, and the rest diagnosed by hospitals in
developing western areas.
Clinical manifestations
PLAM has various clinical manifestations (Table 1). Four-
teen patients experienced pneumatothorax as their initial
symptom, and seven had abdominal symptoms and signs
such as bloating, abdominalgia and mass.
Three patients were complicated with tuberous sclerosis
complex (TSC). One patient was male. He did not undergo
chromosome examination and sex hormones test, but he
had a biological son with his wife. Six patients had been
taking oral contraceptives for a long period of time, and
three patients became pregnant during the disease course.
Lab data
Pulmonary function examinations
The reports of 76 cases included the results of a pulmonary
ventilation test, with 69 testing positive for obstructive
ventilatory functional disturbance, 28 for restrictive
ventilatory functional disturbance, and four cases had
a normal result. Out of 59 patients whose diffusing function
test results were available, 56 had abnormal findings.
However, only a few articles contained specific data for
pulmonary function examination (Table 2).
Imaging findings
119 patients underwent chest CT among whom 4 patients
had mediastinal lymphadenopathy. One patient didn’t have
Table 1 Clinical manifestations.
Clinical manifestations Number of cases
Progressive dyspnea 117(97.5%)
Cough 58(48.3%)
Pneumothorax 51(42.5%)
Hemoptysis 49(40.8%)
Expectoration 43(35.8%)
Chylothorax 34(28.3%)
Chest pain 23(19.2%)
Chyloperitoneum 7 (5.8%)
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not widely available in mainland China in 1980s. Ninety four
patients received HRCT and demonstrated thin-wall cystic
air sacs evenly distributed in bilateral lobes. Only 50
patient reports included abdominal or pelvic CT or B-type
ultrasound findings, with 17 testing positive for lym-
phangioleiomyoma (LALM), 10 positive for renal angiomyo-
lipoma (AML), 1 positive for hepatic AML, 9 complicated
with uterine leiomyoma. Moreover, 5 patients underwent
skull CT and 3 of these patients presented with intracranial
multiple calcification lesions.
Comparison of features of PLAM with and without
AML/LALM
Fifty patient reports included abdominal or pelvic CT or B-
type ultrasound findings, 26 of whom had conditions
complicated with AML/LALM. By comparing these patients
with and without AML/LALM, the former were more to have
pneumothorax and hypoxemia than the latter (PZ 0.019,
0.034 respectively) (Table 3).
Diagnosis
Among these patients, 108 cases were confirmed by
pulmonary biopsy (Fig. 1), 7 by biopsy of the lymph nodes or
other masses, 1 by a combination of the above two biop-
sies, and 4 by clinical diagnosis. Moreover, 2 patients
underwent autopsy, with one demonstrating dramatically
thickened muscularis mucosae and muscular layer in the
jejunum and colon, as well as hypertrophy of smooth
muscle in the wall of the gallbladder.
Eighty two patient reports included documentation of
the duration between symptom onset and a confirmed
diagnosis. The average duration was 29.6 35.8 months
(range: one-half month to 16 years). Eighty person-time
patients had been misdiagnosed before the confirmedTable 2 Pulmonary function.
Variable Number of cases
FEV1/FVC (%) 25 57.7 16.5
FEV1% (%) 25 48.4 18.8
VC% (%) 20 77.0 24.6
DLCO% (%) 16 48.8 18.6
PaO2 (mmHg) 40 59.3 13.3
PaCO2 (mmHg) 36 35.1 9.4diagnosis, 19 of whom were misdiagnosed with idiopathic
interstitial pneumonia, 17 with idiopathic pneumothorax, 9
with emphsema, 7 with pulmonary bulla, 6 with bronchitis,
6 with tuberculosis, 6 with bronchiectasis, 3 with pneu-
monia, 2 with COPD, 2 with asthma, 2 with upper respira-
tory tract infection, 2 with pulmonary involvement of
connective tissue disease, one with pneumoconiosis
complicated with infection, and one with pleuritis.
Regrettably, one PLAM patient had been misdiagnosed with
COPD for as long as 16 years, and another had been diag-
nosed with a string of diseases including chronic bronchitis,
emphysema, pneumonia and idiopathic interstitial pneu-
monia. Peculiarly, four patients were missed for PLAM due
to a lack of pulmonary biopsy because their surgeons failed
to take into account the possibility of PLAM when they
conducted ligation of the pulmonary bulla or thoracic duct
on the patients.
It is worth noting that six patients had experienced
pathological misdiagnosis after pulmonary biopsy, with 4
contributing specimens in the form of transbronchoscopic
lung biopsy (TBLB) and two in thoracoscopy. Fortunately,
three patients were correctly confirmed after a rereading
of the slices, two patients receiving TBLB were correctly
confirmed by thoracoscopy-based pulmonary biopsy, and
one patient was confirmed by repeated TBLB.
Treatment
Antiestrogen therapies
Sixty of the 120 total patients received antiestrogen
medications (Fig. 2). The dosage of progesterone varied
from hospital to hospital, ranging 10-600 mg/d for oral use
and 300e750 mg/m for intramuscular use. A dosage of
400e600 mg/m for intramuscular use was the most common
dosage, and the most frequent length of treatment course
was 6e12 months (maximum length was 5 years). In addi-
tion, three patients had undergone bilateral adnexectomy.
Surgical treatment of the complications
Recurrent pneumatothorax and chylothorax were common
complications for PLAM. Due to pneumatothorax, six
patients had undergone ligation of the pulmonary bulla and
four patients had undergone pleurodesis. Due to chylo-
thorax, four patients had undergone ligation of thoracic
duct and one patient had undergone pleurodesis. Among
the four patients who underwent ligation of the thoracic
duct, two patients did not experience alleviation of their
chylothorax (one of whom underwent two operations), one
patient experienced alleviation, and one patient was not
evaluated.
Pulmonary transplantation
Currently, pulmonary transplantation is the only approach
that can cure PLAM, although cases relapsing in the trans-
planted lung have been reported. Of the cases reviewed
here, four patients had undergone pulmonary trans-
plantation (Table 4).
Table 3 Comparison of features of PLAM with and without AML/LALM.
AML/LALM (nZ 26) Non-AML/LALM (nZ 24) P value
Age at time of confirmed
diagnosis (y)
36.2 7.9 (nZ 26) 36.0 7.2 (nZ 24) 0.914
Course of disease (m)a 44.4 56.1 (nZ 17) 20.8 28.5 (nZ 18) 0.133
Pneumothorax 15/26 6/24 0.019b
Chylothorax 13/26 9/24 0.374
Chyloperitoneum 5/26 1/24 0.192
FEV1/FVC (%) 57.4 12.4 (nZ 7) 60.6 17.7 (nZ 8) 0.689
FEV1% (%) 53.0 20.7 (nZ 7) 51.4 19.1 (nZ 8) 0.879
VC% (%) 87.5 31.2 (nZ 6) 66.2 19.8 (nZ 7) 0.164
DLCO% (%) 57.7 21.5 (nZ 7) 38.8 9.8 (nZ 5) 0.100
PaO2 (mmHg) 55.5 14.4 (nZ 10) 68.6 7.6 (nZ 8) 0.034b
PaCO2 (mmHg) 31.9 6.2 (nZ 10) 38.1 16.5 (nZ 7) 0.295
a Course of disease: the duration between symptom onset and a confirmed diagnosis.
b P< 0.05.
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Twenty-eight PLAM patients were reported to have died
mainly from respiratory failure due to recurrent pneuma-
tothorax or generalized failure due to refractory chylo-
thorax. The average period from confirmed diagnosis to
death was 36.4 48.9 months. The duration from symptom
onset to death was 57.9 40.6 months. A failure to conduct
long-term follow-up of most patients resulted in an
unavailability of precise survival time data.
Discussion
Although studies have demonstrated that PLAM cases have
been increasing in mainland China since 2000, it is scien-
tifically unsound to conclude that the incidence of PLAM is
significantly increasing in mainland China. With doctors in
mainland China becoming more vigilant of PLAM, and as
certain examination approaches (e.g., HRCT) gain in
popularity, some PLAM cases that were previously uncon-
firmed or that had been misdiagnosed for several years
were later found to be confirmed PLAM cases. Additionally,Figure 1 Detailed approaches of pulmonary biopsy. Illustra-
tion: Detailed biopsy approaches were presented by several
papers contributing 97 cases of the 108 cases confirmed by
pulmonary biopsy, in which 49 patients were confirmed by
transbronchoscopic lung biopsy (TBLB), 31 by thoracotomy, 10
by thoracoscopy and 7 by percutaneous pneumocentesis.most PLAM cases (90.8%) were confirmed by hospitals situ-
ated in eastern areas. The fact that the eastern areas are
more developed helps to increase the confirmed diagnosis
rate for the patients in these areas and attracts patients
living in the central and western areas to attend hospitals
situated in the eastern areas. Thus, the higher confirmed
diagnosis rate for PLAM in the eastern areas does not
necessarily indicate that the incidence of PLAM in the
eastern areas is higher than that in the central and western
areas. Since most papers did not provide the native location
of each patient, the authors were unable to analyze the
true geographic distribution of the PLAM cases in mainland
China.
TSC-LAM was reported to account for 15.6% and 14.8% of
the PLAM cases reported in two studies with large samples
conducted by foreign investigators.8,9 In contrast, our
results showed that TSC-LAM accounted for only 2.5% of
cases. We theorize that the discrepancy in these percent-
ages is due to insufficient recognition of the relationship
between PLAM and TSC among doctors in mainland China.
Compared to pulmonary involvement of TSC, the mostFigure 2 Antiestrogen medications. Illustration: 60 patients
had been administered antiestrogen medications, with 48
administered progesterone alone, 2 administered Tamoxifen
alone, one administered Goserelin acetate alone, and 9
administered a combination of two or more antiestrogen
medications, in whom 7 patients received a combination of
progesterone and Tamoxifen.
Table 4 Cases of pulmonary transplantation.
Year of confirmed
diagnosis
Age at confirmed
diagnosis
Year of
operation
Operation approach Prognosis
2002 20 2002 Right middle and low lobes
transplant
Death due to rejection and
infection 27 months after the
operation
2003 42 2003 Single lung transplant Softening and narrowness of
the bronchi 6 months after
transplantation; no follow-up
1995 28 2004 Single lung transplant Underwent opposite pulmonary
transplantation in 2008 and
death due to refractory
chylothorax in the same year
2004 48 2004 Bilateral lung transplant Death due to intratracheal
heavy hemorrhage 29 days
after the operation.
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included epilepsy, mental disorders and skin lesions, and
most symptoms took place in childhood. These symptom
patterns caused many patients to seek help from specialists
in pediatrics, dermatology and the neurosciences, resulting
in a high likelihood of missed diagnosis by the specialists
who are not vigilant to PLAM. Respiratory physicians and
thoracic surgeons can also miss PLAM cases if they only
focus on the PLAM itself without considering the possibility
of pulmonary involvement of TSC. Therefore, specialists of
the above disciplines should be mindful of the association
between PLAM and TSC.
PLAM has various manifestations. The less specific nature
of PLAM,aswell as theabsenceof chest radiographfindings in
the early disease stages, can easily lead to missed diagnoses
or misdiagnoses. We found that the average duration from
symptom onset to the confirmed diagnosis among patients of
mainland China was 2 years or longer. As many as 80 person-
time patients had experiencedmisdiagnosis before receiving
a confirmed diagnosis. There were over 10 diseases
commonly passed for PLAM, themost frequent ofwhichwere
idiopathic interstitial pneumonia and idiopathic pneumo-
thorax. In addition, somePLAMcasesweremissedby thoracic
surgeons because the surgeons conducted ligation of the
pulmonary bulla or thoracic duct to treat the pneumothorax
or chylothorax without performing pathological biopsy.
Thus, raising doctors’ awareness of PLAM, collecting a thor-
ough disease history from all patients, and applying HRCT
when necessary will help healthcare providers avoid misdi-
agnoses and missed diagnoses.
PLAM can involve multiple organs, particularly renal
AML. Studies by Avila et al. showed that in 323 cases of
patients with PLAM, 44.9%, 8.7%, 24.8% of them were
complicated by renal AML, hepatic AML, abdominal or
pelvic LALM, respectively.10 In contrast, the corresponding
rates found in the 120 PLAM cases reviewed here were 8.3%,
0.8% and 13.3%, respectively. We believe that clinicians’
lack of recognition of PLAM as a multi-organ disease is the
primary cause of the low proportion of diagnoses of PLAM
with multiple organ involvement, thereby resulting in
a failure among clinicians to perform necessary abdominal
examinations and to correlate abnormal findings with
PLAM. In addition, our study showed that PLAM patientswith AML/LALM were more likely to have concomitant
pneumothorax and hypoxemia.
It is also important to note that six patients we reviewed
had experienced an incorrect pathological diagnosis, which
may have been caused by an insufficient amount of spec-
imen (possibly due to use of TBLB), by insufficient pathol-
ogist awareness of PLAM or by poor communication
between clinicians and pathologists. In addition, concur-
rent complication from other pulmonary diseases can
complicate the pathological diagnosis of PLAM. Therefore,
when PLAM is strongly suggested by clinical manifestations
and imaging findings but not by pathological results,
rereading the slices or repeating the pathological exam
should be performed in order to avoid incorrect exclusion of
a PLAM diagnosis.
Antiestrogen therapies are considered to be a major
approach for the treatment of PLAM, however, the efficacy
of antiestrogen therapies for the treatment of PLAM is
currently controversial.11e14 Our study found that half of
the 120 patients living in mainland China had been admin-
istered antiestrogen therapies, with progesterone being the
most frequently used. While the recommended dosage of
progesterone in mainland China is an intramuscular injec-
tion of 400e800 mg monthly or an oral use of 10e20 mg
daily,15,16 the patients included in our study had been
administered a wide range of progesterone dosages, from
10 to 600 mg/d for oral use.
Ligation of the thoracic duct is believed to be capable of
treating refractory chylothorax complications related to
PLAM, but its efficacy remains controversial.17,18 Two of the
four patients we reviewed who underwent ligation of the
thoracic duct did not experience alleviation of the chylo-
thorax, which could be explained by obstruction or
destruction of any part of the duct or its branches or the
pleural lymphatic vessels, which will cause chylothorax,
thereby impairing the efficacy of the operation. Ligation
can cause a disturbance of the reflux of chyle from the
branches of the duct or from the pleural lymphatic vessels,
which can further deteriorate chylothorax. Thus, ligation of
the thoracic duct can only be conducted after lymphangi-
ography, depending on which location and type of lesions
can be identified and whether aberrant anatomy of the
thoracic duct can be found.
1526 L. Ye et al.The lack of a national database means that one can only
analyze mainland China PLAM cases by reviewing published
papers describing the casesda method with many short-
comings, especially incompleteness of data. For instance,
some papers we reviewed did not provide the results of
pulmonary function examinations, and most articles only
presented conclusions without providing specific data
values, thereby disabling our statistical analyses across the
cases. Another difficulty is that the cases reported had not
been strictly followed for a long period of time. Only one
third of the papers documented follow-up procedures, with
an average follow-up duration of 28 months. Furthermore,
most of the papers including patient follow-up only evalu-
ated overall patient symptoms, without providing the
results of pulmonary function examinations and imaging
findings during the follow-up. This lack of follow-up data
prevented us from examining changes in the disease over
time and from objectively evaluating the efficacy of the
antiestrogen therapies used.
In summary, our study indicates that doctors in mainland
China are becoming increasingly aware of PLAM, although
misdiagnosis and missed diagnosis still exist. We have three
primary recommendations as a result of our findings: (1)
Doctors inmainlandChinashould improve theirunderstanding
of this rare disease, (2) Doctors in mainland China should be
made aware of and be mindful of the correlation between
PLAM and TSC, as well as the possibility of multiple organ
diseases related to PLAM, and (3) A national agency should be
established in mainland China to oversee PLAM patients with
the purpose of offering better healthcare services to these
patients and facilitating research on this disease.
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